Medicure is a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company’s present focus is the sale and marketing of its cardiovascular products, AGGRASTAT®, ZYPITAMAG® and increasing its e-commerce and mail order pharmaceutical business in all 50 U.S. states through Marley Drug. The cardiovascular products are distributed in the United States and its territories through the Company’s U.S. subsidiary, Medicure Pharma Inc. The Company’s registered office and head office is located at 2-1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6.
Company profile
Ticker
MCUJF
Exchange
Website
CEO
Albert D. Friesen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
MCUJF stock data
Latest filings (excl ownership)
6-K
Medicure Receives Us Fda Fast Track Designation for MC-1 for Pnpo Deficiency
26 Apr 24
20-F
2023 FY
Annual report (foreign)
8 Apr 24
6-K
Current report (foreign)
8 Apr 24
6-K
Current report (foreign)
4 Apr 24
6-K
Current report (foreign)
5 Dec 23
6-K
Medicure Announces Fda Provides Complete Approval to Enroll Patients In Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
24 Nov 23
6-K
Current report (foreign)
21 Nov 23
6-K
Current report (foreign)
5 Sep 23
6-K
Current report (foreign)
24 Jul 23
6-K
Current report (foreign)
31 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Press releases
Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO Deficiency
23 Apr 24
Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
8 Apr 24
Medicure To Present Financial Results on April 9, 2024 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2023
4 Apr 24